The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Optimizing the use of BTK inhibitors in WM: dose reductions & genomic profiling
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the role of BTK inhibitors (BTKis) in the treatment of Waldenström’s macroglobulinemia (WM), highlighting the effectiveness of ibrutinib, acalabrutinib, and zanubrutinib. Dr Castillo emphasizes that dose reductions can be used as a strategy to optimize treatment with BTKis, especially in older patients and women. Genomic profiling, particularly for MYD88, CXCR4, and TP53 mutations, is becoming a key tool in treatment decisions. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
